A Phase 3 interventional study of pregabalin in Neuralgia, Postherpetic, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 33 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-27.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing pregabalin in Neuralgia, Postherpetic — 3 open to participants now, 3 under way, 1 of them phase 3. Pregabalin · Neuralgia, Postherpetic.
Among the 15 studies testing pregabalin in Neuralgia, Postherpetic, this one is the 8th largest by enrollment, is one of 3 that started in 2007, is one of 5 in phase 3, and was the 5th registered.
197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.
Browse Neuralgia, Postherpetic studies →3 of the 15 studies testing pregabalin in Neuralgia, Postherpetic are open now, in 3 countries. Recruiting first, the newest first:
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
Zhejiang Chinese Medical University · Sites in China
Ages 50–80
Neurodawn Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 126 is above the median of 94 across 163 interventional studies indexed under Neuralgia, Postherpetic.
Median enrollment 126 across the 15 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 9 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 8 studies filed under Neuralgia, Postherpetic — fewer than ten, so there is no comparison to draw.
1 of the studies testing pregabalin in Neuralgia, Postherpetic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing pregabalin in Neuralgia, Postherpetic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety of the long-term use of pregabalin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pregabalin
Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
Summary of Adverse Events
Number of subjects with all causality adverse events, serious adverse events, severe adverse events, adverse events resulted in discontinuation, dose reduced or temporary discontinuation. Subjects are counted only once per treatment in each row.
Time frame: 52 weeks
Short-Form McGill Pain Questionnaire the Efficacy of Change: Sensory Score
Score ranges: 0-33. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.
Time frame: 52 weeks
Short-Form McGill Pain Questionnaire the Efficacy of Change: Affective Score
Score ranges: 0-12. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.
Time frame: 52 weeks
Short-Form McGill Pain Questionnaire the Efficacy of Change: Total Score
Score ranges: 0-45. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.
Time frame: 52 weeks
Short-Form McGill Pain Questionnaire the Efficacy of Change: Present Pain Intensity
Score ranges: 0-5. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.
Time frame: 52 weeks
Short-Form McGill Pain Questionnaire the Efficacy of Change: Visual Analog Scale
Ranges: 0-100 mm. Larger scale indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.
Time frame: 52 weeks
| Milestone | Pregabalin |
|---|---|
| Started | 126 |
| Completed | 95 |
| Not completed | 31 |
| Withdrew: Death | 1 |
| Withdrew: Adverse event | 18 |
| Withdrew: Lack of efficacy | 6 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Health deterioration | 1 |
Number of subjects with all causality adverse events, serious adverse events, severe adverse events, adverse events resulted in discontinuation, dose reduced or temporary discontinuation. Subjects are counted only once per treatment in each row.
| subjects | Pregabalin |
|---|---|
| Subjects with adverse events | 124 |
| Subjects with serious adverse events | 14 |
| Subjects with severe adverse events | 5 |
| Subjects discontinued due to adverse events | 17 |
| Dose reduced or temporary discontinuation | 34 |
Score ranges: 0-33. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.
| score on scale | Pregabalin |
|---|---|
| Baseline | 11.3 ± 7.0 |
| Week 52 | 5.1 ± 5.6 |
| Endpoint | 6.7 ± 7.1 |
| Change from Baseline to Endpoint | -4.8 ± 5.9 |
Score ranges: 0-12. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.
| score on scale | Pregabalin |
|---|---|
| Baseline | 3.4 ± 3.1 |
| Week 52 | 1.0 ± 1.8 |
| Endpoint | 1.7 ± 2.7 |
| Change from Baseline to Endpoint | -1.8 ± 2.8 |
Score ranges: 0-45. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.
| score on scale | Pregabalin |
|---|---|
| Baseline | 14.7 ± 9.7 |
| Week 52 | 6.1 ± 7.2 |
| Endpoint | 8.2 ± 9.6 |
| Change from Baseline to Endpoint | -6.5 ± 8.4 |
Score ranges: 0-5. Higher scores indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.
| score on scale | Pregabalin |
|---|---|
| Baseline | 2.8 ± 1.0 |
| Week 52 | 1.4 ± 0.9 |
| Endpoint | 1.7 ± 1.1 |
| Change from Baseline to Endpoint | -1.1 ± 1.1 |
Ranges: 0-100 mm. Larger scale indicate more severe pain. Baseline: The last evaluation on or before Day 1 of double-blind for subjects that took pregabalin in double-blind and last visit \<= Day 1 of open-label for subjects that took placebo in double-blind. Endpoint: The last evaluation during dose adjustment/maintenance step of open-label.
| mm | Pregabalin |
|---|---|
| Baseline | 62.0 ± 19.0 |
| Week 52 | 28.3 ± 22.9 |
| Endpoint | 33.7 ± 25.6 |
| Change from Baseline to Endpoint | -28.3 ± 23.8 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 15/126 (11.9%) | 98/126 (77.8%) |
| Event | Pregabalin |
|---|---|
| Spinal compression fractureInjury, poisoning and procedural complications | 2/126 |
| Atrial fibrillationCardiac disorders | 1/126 |
| Cardiac failure congestiveCardiac disorders | 1/126 |
| VertigoEar and labyrinth disorders | 1/126 |
| Gastroduodenal ulcerGastrointestinal disorders | 1/126 |
| Chest painGeneral disorders | 1/126 |
| PneumoniaInfections and infestations | 1/126 |
| Heat strokeInjury, poisoning and procedural complications | 1/126 |
| Joint dislocationInjury, poisoning and procedural complications | 1/126 |
| Open fractureInjury, poisoning and procedural complications | 1/126 |
| Event | Pregabalin |
|---|---|
| DizzinessNervous system disorders | 36/126 |
| NasopharyngitisInfections and infestations | 34/126 |
| Oedema peripheralGeneral disorders | 22/126 |
| SomnolenceNervous system disorders | 22/126 |
| Weight increasedInvestigations | 19/126 |
| ConstipationGastrointestinal disorders | 12/126 |
| DiarrhoeaGastrointestinal disorders | 12/126 |
| FallInjury, poisoning and procedural complications | 9/126 |
| Retinal haemorrhageEye disorders | 7/126 |
| Visual acuity reducedEye disorders | 7/126 |
| Age, Customized(Subjects) | Pregabalin |
|---|---|
| >= 18 and < 45 years | 1 |
| >= 45 and < 65 years | 19 |
| >=65 years | 106 |
| Sex: Female, Male(Participants) | Pregabalin |
|---|---|
| Female | 55 |
| Male | 71 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jan 2007 to primary completion in Aug 2008, 19 months.
Results were first posted in Sep 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →